EP2726071B1 - Topical formulations including lipid microcapsule delivery vehicles and their uses - Google Patents
Topical formulations including lipid microcapsule delivery vehicles and their uses Download PDFInfo
- Publication number
- EP2726071B1 EP2726071B1 EP12804394.0A EP12804394A EP2726071B1 EP 2726071 B1 EP2726071 B1 EP 2726071B1 EP 12804394 A EP12804394 A EP 12804394A EP 2726071 B1 EP2726071 B1 EP 2726071B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- topical formulation
- vitamin
- topical
- lipid microcapsule
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002632 lipids Chemical class 0.000 title claims description 69
- 239000003094 microcapsule Substances 0.000 title claims description 68
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims description 54
- 239000000203 mixture Substances 0.000 claims description 62
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 57
- 239000013543 active substance Substances 0.000 claims description 45
- 239000011647 vitamin D3 Substances 0.000 claims description 42
- 235000005282 vitamin D3 Nutrition 0.000 claims description 42
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 42
- 229940021056 vitamin d3 Drugs 0.000 claims description 42
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 32
- 239000003381 stabilizer Substances 0.000 claims description 32
- 239000004094 surface-active agent Substances 0.000 claims description 32
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 30
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 28
- 239000011732 tocopherol Substances 0.000 claims description 28
- 229930003799 tocopherol Natural products 0.000 claims description 28
- 235000010384 tocopherol Nutrition 0.000 claims description 28
- 229960001295 tocopherol Drugs 0.000 claims description 28
- 239000011731 tocotrienol Substances 0.000 claims description 28
- 229930003802 tocotrienol Natural products 0.000 claims description 28
- 235000019148 tocotrienols Nutrition 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- -1 polyoxyethylene Polymers 0.000 claims description 24
- 230000000699 topical effect Effects 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 21
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 18
- 229960002061 ergocalciferol Drugs 0.000 claims description 18
- 239000011653 vitamin D2 Substances 0.000 claims description 18
- 235000001892 vitamin D2 Nutrition 0.000 claims description 18
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 18
- 239000003223 protective agent Substances 0.000 claims description 17
- 229930003316 Vitamin D Natural products 0.000 claims description 15
- 235000019166 vitamin D Nutrition 0.000 claims description 15
- 239000011710 vitamin D Substances 0.000 claims description 15
- 229940046008 vitamin d Drugs 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims description 5
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 230000003185 calcium uptake Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 208000012672 seasonal affective disease Diseases 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000011874 heated mixture Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- NMSBTWLFBGNKON-UHFFFAOYSA-N 2-(2-hexadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCO NMSBTWLFBGNKON-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940060184 oil ingredients Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003365 short chain fatty acid esters Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention relates to topical formulations that include lipid microcapsules, in particular lipid microcapsules for the transdermal delivery of therapeutic agents into the bloodstream.
- lipid vesicles which require steroids, oils and charge-producing agents (e.g., oleic acid, dactyl phosphate, cetyl sulphate, phosphatidic acid, phosphatidyl serine, and/or mixtures thereof) for their formation (see, for example, U.S. Patent No. 4,911,928 to Wallach ); and micellar nanoparticles, which contain oils and require initiators (see, for example, U.S. Patent No. 5,629,021 to Wright ).
- oils and charge-producing agents e.g., oleic acid, dactyl phosphate, cetyl sulphate, phosphatidic acid, phosphatidyl serine, and/or mixtures thereof
- micellar nanoparticles which contain oils and require initiators (see, for example, U.S. Patent No. 5,629,021 to Wright ).
- the present invention is directed to topical formulations which include a lipid microcapsule, the lipid microcapsule comprised of tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component selected from polyoxyethylene (2) stearyl ether, polyoxyethylene (2) cetyl ether and a mixture thereof; and an aqueous component, wherein said lipid microcapsule is formed by the steps (i) adding said tocopherol, tocotrienol, or mixtures thereof to said stabilizer/surfactant component to produce a mixture; (ii) heating said mixture; and (iii) adding said aqueous component to said heated mixture thereby forming said lipid microcapsule; and wherein said lipid microcapsule is free of a phospholipid charge-producing agent.
- the tocopherol, tocotrienol, or mixtures thereof; the stabilizer/surfactant component; and the aqueous component form, in combination, a lipophilic phase of the topical formulation.
- the tocopherol, tocotrienol, or mixtures thereof are present in the lipid microcapsule in an amount of about 0 ⁇ % to about 5% based on the total weight of the topical formulation.
- the aqueous component is present in the lipid microcapsule in an amount of about 58% to about 95% based on the total weight of the topical formulation.
- the stabilizer/surfactant component is present in the lipid microcapsule in an amount of about 7% to about 13% based on the total weight of the topical formulation.
- the aqueous component of the lipid microcapsule is a physiologically compatible solution.
- the aqueous component of the lipid microcapsule is water.
- the topical formulation is free of a skin penetration enhancer.
- the topical formulation is free of a steroid compound
- the topical formulation is free of a preservative compound.
- the topical formulation is free of an initiator compound.
- the topical formulation is free of a charge-producing compound.
- the topical formulation is free of an oil compound.
- the topical formulation further includes one or more transdermal active agents dissolved, suspended or encapsulated in the lipid microcapsule.
- the one or more transdermal active agents is dissolved, suspended and/or dispersed in the aqueous component of the lipid microcapsule.
- the one or more transdermal active agents is a vitamin D compound.
- the vitamin D compound is present in the topical formulation in an amount of about 0 ⁇ % to about 30%.
- the vitamin D compound is a physiologic biological vitamin D compound.
- the vitamin D compound is selected from the group consisting of cholecalciferol, ergocalciferol, and mixtures thereof.
- the lipid microcapsule upon topical application of the topical formulation to a mammal, delivers the one or more transdermal active agents transdermally to the bloodstream of the mammal.
- the topical formulation further includes one or more topical active agents.
- the one or more topical active agents is present outside the lipid microcapsule such that the lipid microcapsule is free of the one or more topical active agents.
- the one or more topical active agents remains substantially epicutaneous and is not substantially delivered transdermally to the bloodstream of the mammal.
- the one or more topical active agents substantially remains on the skin of the mammal.
- the one or more topical active agents is a sun-protecting agent.
- the sun-protecting agent is present in the topical formulation in an amount of about 0 ⁇ % to about 30% based on the total weight of the topical formulation.
- the topical formulation is in the form of a cream, gel, liquid, lotion, solution, spray, emulsion, aerosol, or a combination thereof.
- the present invention is to topical formulations including: (a) a lipid microcapsule, the lipid microcapsule comprised of tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component; and an aqueous component; (b) one or more transdermal active agents, the one or more transdermal active agents being dissolved, suspended or encapsulated in the lipid microcapsule; and, optionally, (c) one or more topical active agents, wherein the one or more topical active agents is present outside the lipid microcapsule such that the lipid microcapsule is free of the one or more topical active agents; wherein the topical formulation is free of skin penetration enhancers; and wherein, upon topical application of the topical formulation to a mammal, the one or more transdermal active agents is delivered transdermally to the bloodstream of the mammal; and the one or more topical active agents remains substantially epicutaneous and is not delivered substantially transdermally to the bloodstream of the mammal.
- topical formulation is free of initiators.
- a method of treatment includes topically administering a therapeutically effective amount of a topical formulation according to the present invention having a transdermal active agent that is a vitamin D compound.
- the method of treatment is effective for the treatment of a disorder or disease associated with vitamin D deficiency or vitamin D insufficiency.
- the method of treatment is effective for the treatment of a disorder or disease selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer.
- a disorder or disease selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer.
- the present invention is also directed to a topical formulation according to the present disclosure for use in treating a disorder or disease associated with vitamin D deficiency or vitamin D insufficiency, wherein said transdermal active agent is a vitamin D compound; said disorder of disease associated with vitamin D deficiency or vitamin D insufficiency being selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer.
- the present disclosure is directed to a therapeutic method of treatment, including administering to a mammal a topical formulation according to the present invention including a sun-protecting agent.
- a topical formulation according to the present invention including a sun-protecting agent.
- the present invention relates to topical formulations that include lipid microcapsules, in particular lipid microcapsules for the transdermal delivery of therapeutic agents into the bloodstream.
- the present invention is directed to new topical formulations that include new lipid microcapsule delivery vehicles for the transdermal delivery of therapeutic agents into the bloodstream.
- Lipid microcapsules according to the present invention include tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component (such terms being used interchangeably herein) selected from polyoxyethylene (2) stearyl ether, polyoxyethylene (2) cetyl ether and a mixture thereof, which is involved in formation of the lipid microcapsule wall; and an aqueous component, such as water or buffer.
- a stabilizer/surfactant component such terms being used interchangeably herein
- an aqueous component such as water or buffer.
- stabilizers/surfactants examples include, for example and without limitation, those set forth in Tables 1 and 2, below. It is believed that the high molecular weight of these stabilizers/surfactants imparts advantageous properties to the lipid microcapsules according to the present invention, particularly with respect to manufacture and stability.
- Lipid microcapsules according to the present disclosure are useful as delivery system/delivery vehicles (such terms being used interchangeably herein), in particular for the therapeutic delivery of drugs and/or active agents, and more particularly for the topical delivery of hydrophilic or hydrophobic materials, for example to administer a drug and/or active agent to a patient transdermally.
- Lipid microcapsules according to the present disclosure are compatible with bodily tissues, and therefore they are useful as delivery vehicles for numerous therapeutic and other applications.
- Lipid microcapsules according to the present disclosure are particularly useful as topical drug and active ingredient delivery vehicles as their structural characteristics permit dermal penetration. They are also exceptionally versatile in that the active agents which may be carried include those which are fat-soluble or water-soluble, and which may be suspended or dissolved. These properties allow lipid microcapsules according to the present disclosure to be used with ingredients that are difficult to use in conventional delivery systems, without the costs of many additive chemicals and/or enhancers.
- lipid microcapsules according to the present disclosure may be formed without the use of steroids (such as cholesterol, hydrocortisone and/or analogs or derivatives thereof), preservatives, initiators (such as ethanol, methanol and other short chain alcohols and/or amides), charge-producing substances (such as oleic acid, dicetyl phosphate, cetyl sulphate, phosphatidic acid, phosphatidyl serine, and/or mixtures thereof), and/or oil ingredients, and therefore have various advantages over delivery vehicles formed using one or more such ingredients.
- steroids such as cholesterol, hydrocortisone and/or analogs or derivatives thereof
- preservatives such as ethanol, methanol and other short chain alcohols and/or amides
- charge-producing substances such as oleic acid, dicetyl phosphate, cetyl sulphate, phosphatidic acid, phosphatidyl serine, and/or mixtures thereof
- charge-producing substances such as oleic acid, dice
- topical formulations according to the present disclosure do not require skin penetration enhancers (such as aprotic solvents, alcohols, and short chain fatty acid esters) to transdermally deliver the active agent(s) contained within the lipid microcapsules through the skin and into the bloodstream.
- skin penetration enhancers such as aprotic solvents, alcohols, and short chain fatty acid esters
- lipid microcapsules according to the present disclosure may be modified or custom manufactured by increasing or decreasing the amount of aqueous hydration, to achieve certain desired properties.
- lipid microcapsules may optionally be added to lipid microcapsules according to the present disclosure, to achieve certain desired properties.
- Coloring agents such as, for example, food coloring agents
- flavorings and scents may also optionally be used in forming lipid microcapsules according to the present disclosure, to achieve certain desired properties (for example and without limitation, in the formation of products intended for application to the lips).
- Lipid microcapsules according to the present disclosure transport/carry (such terms being used interchangeably herein) drugs and/or active agents which are suspended and/or incorporated into the final, formed lipid microcapsules.
- drugs and/or active agent may, for example and without limitation, be dissolved, or suspended on or in the lipid microcapsules.
- the drug and/or active agent may be cholecalciferol or ergocalciferol, which may be suspended or incorporated into lipid microcapsules according to the present disclosure.
- the aqueous solution used to hydrate the lipophilic phase in forming lipid microcapsules according to the present disclosure may be, in certain embodiments, a physiologically compatible solution, such as water.
- the aqueous solution may have transdermal active agent(s) dissolved or suspended therein for incorporation.
- the basic procedure for the manufacture of lipid microcapsules according to the preset invention is to blend the tocopherol, tocotrienol and/or mixtures thereof and the stabilizer/surfactant ingredient, to thereby form a lipophilic phase.
- the transdermal active agent(s) to be transported such as cholecalciferol and/or ergocalciferol, may be added and mixed in this phase.
- a step may be the addition to the mixture of any other ingredients, for example and without limitation, topical active agent(s) such as sun-protecting agents.
- topical active agent(s) are added to the mixture, they are not substantially suspended or encapsulated in the lipid microcapsules, and accordingly the topical formulations of the present disclosure may, in such an embodiment, have a bimodal functionality, wherein the single formulation is capable of delivering transdermal active agent(s) through the skin and into the bloodstream (i.e., an agent suspended or encapsulated in the lipid microcapsule) while concurrently delivering topical active agent(s) to the surface of the skin, where it remains (i.e., an agent which is not suspended or encapsulated in the lipid microcapsules).
- the materials and processes described herein may be selected and/or modified to control the properties, as desired, of the resulting lipid microcapsules according to the present disclosure.
- Active agents may, for example, be carried in the aqueous phase for suspension and incorporation into the inventive lipid microcapsules.
- lipid microcapsules according to the present disclosure may be made using USP or NF grade materials suitable for human applications, such as when they are to be used for the topical delivery of a drug and/or active agent (for example, and without limitation, a fat soluble active agent such cholecalciferol or ergocalciferol) into the bloodstream.
- a drug and/or active agent for example, and without limitation, a fat soluble active agent such cholecalciferol or ergocalciferol
- lipid microcapsules according to the present disclosure may be used to encapsulate and deliver/transport a broad spectrum of materials; may provide a delivery vehicle for the transport of fat-soluble and/or water soluble materials; may provide a vehicle for the topical delivery of active agents such as cholecalciferol and/or ergocalciferol; may be produced in a rapid manner and/or using relatively inexpensive materials; and/or may be mixable in water and may be stored at room temperature.
- active agents such as cholecalciferol and/or ergocalciferol
- lipid microcapsules may be produced according to the present disclosure incorporating drugs and/or active ingredients, and other suitable materials, including lipid microcapsules for the transdermal delivery of such drugs and/or active ingredients.
- lipid microcapsules according to the present disclosure may be formed by first combining tocopherol, tocotrienol and/or mixtures thereof and a stabilizer/surfactant ingredient (such as polyoxyethylene (2) stearyl ether (Brij 74) or polyoxyethylene (2) cetyl ether (Brij 52)).
- a stabilizer/surfactant ingredient such as polyoxyethylene (2) stearyl ether (Brij 74) or polyoxyethylene (2) cetyl ether (Brij 52)
- Table 1 Exemplary Formulation Ingredient Amount Tocopherol/Tocotrienol: Vitamin E USP 0 ⁇ % to 5% Stabilizer/Surfactant (e.g., polyoxyethylene (2) stearyl ether (Brij 74) or polyoxyethylene (2) cetyl ether (Brij 52)) 7% to 13% Aqueous Solution 58% to 95% Sun-protecting agents (e.g., ZnO 2 , TiO 2 ) 0% to 25% (varies based on desired sun-protecting factor) Table 2: Exemplary Formulations Min g ⁇ Max g ⁇ Water 584 950 Polyoxyethylene 2-stearyl ether 65 130 Alpha tocopherol 0 ⁇ 50 Cholecalciferol 0 ⁇ 25 Zinc Oxide 24 253 Titanium Dioxide 0 ⁇ 102 * components measured in grams when admixed yield approximately 1kg per batch
- topical formulations of the present disclosure may be prepared by those of skill in the art, for example and without limitation, on the basis of the teachings provided herein, and according to the ranges of ingredients shown in Table 3.
- Table 3 Exemplary Formulations Ingredient Range of Amounts Tocopherol, Tocotrienol or Mixture 0 ⁇ % to about 20% Tocopherol, Tocotrienol or Mixture 0 ⁇ % to about 15% Tocopherol, Tocotrienol or Mixture 0 ⁇ % to about 10% Tocopherol, Tocotrienol or Mixture 0 ⁇ % to about 5% Tocopherol, Tocotrienol or Mixture about 1% to about 5% Tocopherol, Tocotrienol or Mixture about 2% to about 5% Tocopherol, Tocotrienol or Mixture about 3% to about 5% Tocopherol, Tocotrienol or Mixture about 4% to about 5% Tocopherol, Tocotrienol or Mixture about 5% to about 9% Tocopherol, Tocotrienol or Mixture about 5% to about 8% Tocopherol, Tocotrienol or Mixture about 5% to about 7% Tocopherol, Tocotrienol or Mixture about 5% to about 6% To
- capsule size may be modified by decreasing or increasing the water content; decreasing or increasing the stabilizer/surfactant content; and/or by changing the temperature or the shear in forming lipid microcapsules according to the present disclosure.
- a vitamin D-sunscreen cream formulation of the present invention was prepared within the parameters set forth in Table 4 and as described herein ("test formulation").
- Table 4 Test Formulation Vitamin E USP(E) Polyoxyethylene-1-stearyl ether (B72) Sterile USP Water Vitamin D3 USP (30,000IU per gram) in corn oil Zinc Oxide USP micronized powder (8%)
- Subjects agreed as follows: not to apply moisturizers or other topical skin care or prescription skin care products to the test formulation application sites during the study; to use the sunscreen on areas of potential sun exposure not covered by the test formulation; agreed to apply the test formulation once daily after bathing; to maintain their pre-study lifestyle and to not change daily activities that would change their exposure to the sun; and not to ingest vitamins or other supplements that contain any form of vitamin D within 30 days of the first visit.
- Vitamin D3 levels were measured at Days -7 (Screening), 0 (Baseline), 7, 14, 21, 28 and 35.
- a pre-specified endpoint was a numerically significant difference between baseline vitamin D3 and end of study vitamin D3. Vitamin D3 levels were assessed as percent change from baseline. Ordinal investigator tolerability assessments were evaluated with a Mann Whitney two-tailed t-test for nonparametric data.
- Table 5 Serum vitamin D3 Levels Week -1 to Week 5 Vitamin D3 Levels (ng/ml) Subject Day -7 (Screen) Day 0 (Baseline) Day 7 Day 14 Day 21 Day 28 Day 35 1 14.7 16.0 15.2 14.8 14.6 14.9 17.9 2 18.3 18.6 17.4 20.0 18.4 21.8 21.9 3 16.3 17.5 17.0 16.7 17.1 20.7 23.1
- FIGS.1A-1C ; 2A-2C ; and 3A-3C show analysis of the data in Table 5, as follows:
- FIGS. 1A-1C show vitamin D3 levels measured from baseline (Week 0) to the end of study (Week 5). Mean increase in vitamin D3 levels was 21% (per protocol analysis).
- FIGS.2A-2C show vitamin D3 levels measured from the lowest D3 level to the end of study (Week 5). Mean increase in vitamin D3 levels was 30% (by intent analysis).
- FIGS.3A-3C show vitamin D3 levels measured from Week 3 to the end of study (Week 5). Mean increase in vitamin D3 levels was 26% (per best case analysis).
- topical formulations and lipid microcapsules according to the present invention may further include other ingredients, as necessary to render formulations suitable for specific applications.
Description
- The present invention relates to topical formulations that include lipid microcapsules, in particular lipid microcapsules for the transdermal delivery of therapeutic agents into the bloodstream.
- Conventional delivery systems, such as for pharmaceutical agents, include lipid vesicles, which require steroids, oils and charge-producing agents (e.g., oleic acid, dactyl phosphate, cetyl sulphate, phosphatidic acid, phosphatidyl serine, and/or mixtures thereof) for their formation (see, for example,
U.S. Patent No. 4,911,928 to Wallach ); and micellar nanoparticles, which contain oils and require initiators (see, for example,U.S. Patent No. 5,629,021 to Wright ). - As is known to those in the art, such conventional delivery systems have various drawbacks as a result of the ingredients used in their formation. Accordingly, there is a need in the art for new and improved delivery systems, particularly for the delivery of pharmaceutical agents. It is therefore objects of the present invention to provide such delivery systems, as well as methods for making and using the same.
- The invention is defined by the appended claims. Any embodiment not falling under the scope of the appended claims does not form part of the invention. The present invention is directed to topical formulations which include a lipid microcapsule, the lipid microcapsule comprised of tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component selected from polyoxyethylene (2) stearyl ether, polyoxyethylene (2) cetyl ether and a mixture thereof; and an aqueous component, wherein said lipid microcapsule is formed by the steps (i) adding said tocopherol, tocotrienol, or mixtures thereof to said stabilizer/surfactant component to produce a mixture; (ii) heating said mixture; and (iii) adding said aqueous component to said heated mixture thereby forming said lipid microcapsule; and
wherein said lipid microcapsule is free of a phospholipid charge-producing agent. - In certain exemplary embodiments, the tocopherol, tocotrienol, or mixtures thereof; the stabilizer/surfactant component; and the aqueous component form, in combination, a lipophilic phase of the topical formulation.
- In certain exemplary embodiments, the tocopherol, tocotrienol, or mixtures thereof are present in the lipid microcapsule in an amount of about 0<% to about 5% based on the total weight of the topical formulation.
- In certain exemplary embodiments, the aqueous component is present in the lipid microcapsule in an amount of about 58% to about 95% based on the total weight of the topical formulation.
- In certain exemplary embodiments, the stabilizer/surfactant component is present in the lipid microcapsule in an amount of about 7% to about 13% based on the total weight of the topical formulation.
- In certain exemplary embodiments, the aqueous component of the lipid microcapsule is a physiologically compatible solution.
- In certain exemplary embodiments, the aqueous component of the lipid microcapsule is water.
- In certain exemplary embodiments, the topical formulation is free of a skin penetration enhancer.
- In certain exemplary embodiments, the topical formulation is free of a steroid compound
- In certain exemplary embodiments, the topical formulation is free of a preservative compound.
- In certain exemplary embodiments, the topical formulation is free of an initiator compound.
- The topical formulation is free of a charge-producing compound.
- In certain exemplary embodiments, the topical formulation is free of an oil compound.
- In certain exemplary embodiments, the topical formulation further includes one or more transdermal active agents dissolved, suspended or encapsulated in the lipid microcapsule.
- In certain exemplary embodiments, the one or more transdermal active agents is dissolved, suspended and/or dispersed in the aqueous component of the lipid microcapsule.
- In certain exemplary embodiments, the one or more transdermal active agents is a vitamin D compound.
- In certain exemplary embodiments, the vitamin D compound is present in the topical formulation in an amount of about 0<% to about 30%.
- In certain exemplary embodiments, the vitamin D compound is a physiologic biological vitamin D compound.
- In certain exemplary embodiments, the vitamin D compound is selected from the group consisting of cholecalciferol, ergocalciferol, and mixtures thereof.
- In an example, upon topical application of the topical formulation to a mammal, the lipid microcapsule delivers the one or more transdermal active agents transdermally to the bloodstream of the mammal.
- In certain exemplary embodiments, the topical formulation further includes one or more topical active agents.
- In certain exemplary embodiments, the one or more topical active agents is present outside the lipid microcapsule such that the lipid microcapsule is free of the one or more topical active agents.
- In an example, the one or more topical active agents remains substantially epicutaneous and is not substantially delivered transdermally to the bloodstream of the mammal.
- In an example, the one or more topical active agents substantially remains on the skin of the mammal.
- In certain exemplary embodiments, the one or more topical active agents is a sun-protecting agent.
- In certain exemplary embodiments, the sun-protecting agent is present in the topical formulation in an amount of about 0<% to about 30% based on the total weight of the topical formulation.
- In certain exemplary embodiments, the topical formulation is in the form of a cream, gel, liquid, lotion, solution, spray, emulsion, aerosol, or a combination thereof.
- In an example, the present invention is to topical formulations including: (a) a lipid microcapsule, the lipid microcapsule comprised of tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component; and an aqueous component; (b) one or more transdermal active agents, the one or more transdermal active agents being dissolved, suspended or encapsulated in the lipid microcapsule; and, optionally, (c) one or more topical active agents, wherein the one or more topical active agents is present outside the lipid microcapsule such that the lipid microcapsule is free of the one or more topical active agents; wherein the topical formulation is free of skin penetration enhancers; and wherein, upon topical application of the topical formulation to a mammal, the one or more transdermal active agents is delivered transdermally to the bloodstream of the mammal; and the one or more topical active agents remains substantially epicutaneous and is not delivered substantially transdermally to the bloodstream of the mammal.
- In an example, the topical formulation is free of initiators.
- Disclosed is also a methods of administration, including topically administering to a mammal a topical formulation according to the present disclosure.
- A method of treatment includes topically administering a therapeutically effective amount of a topical formulation according to the present invention having a transdermal active agent that is a vitamin D compound.
- The method of treatment is effective for the treatment of a disorder or disease associated with vitamin D deficiency or vitamin D insufficiency.
- The method of treatment is effective for the treatment of a disorder or disease selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer.
The present invention is also directed to a topical formulation according to the present disclosure for use in treating a disorder or disease associated with vitamin D deficiency or vitamin D insufficiency, wherein said transdermal active agent is a vitamin D compound; said disorder of disease associated with vitamin D deficiency or vitamin D insufficiency being selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer. - In an example, the present disclosure is directed to a therapeutic method of treatment, including administering to a mammal a topical formulation according to the present invention including a sun-protecting agent.
Any references in the description to method of treatment refer to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body be therapy. -
-
FIGS. 1A-1C show vitamin D3 levels measured from baseline (Week 0) to the end of study (Week 5). Mean increase in vitamin D3 levels was 21%. -
FIGS.2A-2C show vitamin D3 levels measured from the lowest D3 level to the end of study (Week 5). Mean increase in vitamin D3 levels was 30%. -
FIGS.3A-3C show vitamin D3 levels measured fromWeek 3 to the end of study (Week 5). Mean increase in vitamin D3 levels was 26%. - The present invention relates to topical formulations that include lipid microcapsules, in particular lipid microcapsules for the transdermal delivery of therapeutic agents into the bloodstream.
- Generally speaking, and as discussed in greater detail in the illustrative and non-limiting Examples provided herein, the present invention is directed to new topical formulations that include new lipid microcapsule delivery vehicles for the transdermal delivery of therapeutic agents into the bloodstream.
- Lipid microcapsules according to the present invention include tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component (such terms being used interchangeably herein) selected from polyoxyethylene (2) stearyl ether, polyoxyethylene (2) cetyl ether and a mixture thereof, which is involved in formation of the lipid microcapsule wall; and an aqueous component, such as water or buffer.
- Examples of stabilizers/surfactants which may be used include, for example and without limitation, those set forth in Tables 1 and 2, below. It is believed that the high molecular weight of these stabilizers/surfactants imparts advantageous properties to the lipid microcapsules according to the present invention, particularly with respect to manufacture and stability.
- Lipid microcapsules according to the present disclosure are useful as delivery system/delivery vehicles (such terms being used interchangeably herein), in particular for the therapeutic delivery of drugs and/or active agents, and more particularly for the topical delivery of hydrophilic or hydrophobic materials, for example to administer a drug and/or active agent to a patient transdermally. Lipid microcapsules according to the present disclosure are compatible with bodily tissues, and therefore they are useful as delivery vehicles for numerous therapeutic and other applications.
- Lipid microcapsules according to the present disclosure are particularly useful as topical drug and active ingredient delivery vehicles as their structural characteristics permit dermal penetration. They are also exceptionally versatile in that the active agents which may be carried include those which are fat-soluble or water-soluble, and which may be suspended or dissolved. These properties allow lipid microcapsules according to the present disclosure to be used with ingredients that are difficult to use in conventional delivery systems, without the costs of many additive chemicals and/or enhancers.
- In certain embodiments, and as described herein, lipid microcapsules according to the present disclosure may be formed without the use of steroids (such as cholesterol, hydrocortisone and/or analogs or derivatives thereof), preservatives, initiators (such as ethanol, methanol and other short chain alcohols and/or amides), charge-producing substances (such as oleic acid, dicetyl phosphate, cetyl sulphate, phosphatidic acid, phosphatidyl serine, and/or mixtures thereof), and/or oil ingredients, and therefore have various advantages over delivery vehicles formed using one or more such ingredients.
- In certain embodiments, topical formulations according to the present disclosure do not require skin penetration enhancers (such as aprotic solvents, alcohols, and short chain fatty acid esters) to transdermally deliver the active agent(s) contained within the lipid microcapsules through the skin and into the bloodstream.
- Additionally, lipid microcapsules according to the present disclosure may be modified or custom manufactured by increasing or decreasing the amount of aqueous hydration, to achieve certain desired properties.
- Various other materials may optionally be added to lipid microcapsules according to the present disclosure, to achieve certain desired properties.
- Coloring agents (such as, for example, food coloring agents), flavorings and scents may also optionally be used in forming lipid microcapsules according to the present disclosure, to achieve certain desired properties (for example and without limitation, in the formation of products intended for application to the lips).
- Lipid microcapsules according to the present disclosure transport/carry (such terms being used interchangeably herein) drugs and/or active agents which are suspended and/or incorporated into the final, formed lipid microcapsules. Such drugs and/or active agent may, for example and without limitation, be dissolved, or suspended on or in the lipid microcapsules. For example and without limitation, in certain embodiments the drug and/or active agent may be cholecalciferol or ergocalciferol, which may be suspended or incorporated into lipid microcapsules according to the present disclosure.
- The aqueous solution used to hydrate the lipophilic phase in forming lipid microcapsules according to the present disclosure may be, in certain embodiments, a physiologically compatible solution, such as water. The aqueous solution may have transdermal active agent(s) dissolved or suspended therein for incorporation. The basic procedure for the manufacture of lipid microcapsules according to the preset invention is to blend the tocopherol, tocotrienol and/or mixtures thereof and the stabilizer/surfactant ingredient, to thereby form a lipophilic phase. The transdermal active agent(s) to be transported, such as cholecalciferol and/or ergocalciferol, may be added and mixed in this phase. A step may be the addition to the mixture of any other ingredients, for example and without limitation, topical active agent(s) such as sun-protecting agents.
- If topical active agent(s) are added to the mixture, they are not substantially suspended or encapsulated in the lipid microcapsules, and accordingly the topical formulations of the present disclosure may, in such an embodiment, have a bimodal functionality, wherein the single formulation is capable of delivering transdermal active agent(s) through the skin and into the bloodstream (i.e., an agent suspended or encapsulated in the lipid microcapsule) while concurrently delivering topical active agent(s) to the surface of the skin, where it remains (i.e., an agent which is not suspended or encapsulated in the lipid microcapsules).
- As will be understood to those of skill in the art, the materials and processes described herein may be selected and/or modified to control the properties, as desired, of the resulting lipid microcapsules according to the present disclosure. Active agents may, for example, be carried in the aqueous phase for suspension and incorporation into the inventive lipid microcapsules.
- Furthermore, lipid microcapsules according to the present disclosure may be made using USP or NF grade materials suitable for human applications, such as when they are to be used for the topical delivery of a drug and/or active agent (for example, and without limitation, a fat soluble active agent such cholecalciferol or ergocalciferol) into the bloodstream.
- In certain exemplary, non-limiting embodiments, lipid microcapsules according to the present disclosure may be used to encapsulate and deliver/transport a broad spectrum of materials; may provide a delivery vehicle for the transport of fat-soluble and/or water soluble materials; may provide a vehicle for the topical delivery of active agents such as cholecalciferol and/or ergocalciferol; may be produced in a rapid manner and/or using relatively inexpensive materials; and/or may be mixable in water and may be stored at room temperature.
- According to the teachings provided herein, it is understood that those of skill in the art may produce lipid microcapsules according to the present disclosure incorporating drugs and/or active ingredients, and other suitable materials, including lipid microcapsules for the transdermal delivery of such drugs and/or active ingredients.
- In this regard, and without limitation, lipid microcapsules according to the present disclosure may be formed by first combining tocopherol, tocotrienol and/or mixtures thereof and a stabilizer/surfactant ingredient (such as polyoxyethylene (2) stearyl ether (Brij 74) or polyoxyethylene (2) cetyl ether (Brij 52)).
- After heating and pre-mixing of the materials, water is added to the mixture. An exemplary formulation showing the amounts of tocopherol, tocotrienol, and mixtures thereof; stabilizer/surfactant component; aqueous component, and optional sun-protecting agent that may be used is shown in Table 1; other exemplary formulations are shown in Table 2.
- Unless otherwise specified, percentages provided herein refer to that based on the weight of the total formulation.
Table 1: Exemplary Formulation Ingredient Amount Tocopherol/Tocotrienol: Vitamin E USP 0<% to 5% Stabilizer/Surfactant (e.g., polyoxyethylene (2) stearyl ether (Brij 74) or polyoxyethylene (2) cetyl ether (Brij 52)) 7% to 13% Aqueous Solution 58% to 95% Sun-protecting agents (e.g., ZnO2, TiO2) 0% to 25% (varies based on desired sun-protecting factor) Table 2: Exemplary Formulations Min g∗ Max g∗ Water 584 950 Polyoxyethylene 2-stearyl ether 65 130 Alpha tocopherol 0< 50 Cholecalciferol 0< 25 Zinc Oxide 24 253 Titanium Dioxide 0< 102 * components measured in grams when admixed yield approximately 1kg per batch - Further exemplary topical formulations of the present disclosure may be prepared by those of skill in the art, for example and without limitation, on the basis of the teachings provided herein, and according to the ranges of ingredients shown in Table 3.
- It is to be understood that the ingredients and ranges show in Table 3 are illustrative only and are not to be viewed as a limitation on the present invention, and that each possible combination of tocopherol, tocotrienol, and mixtures thereof; stabilizer/surfactant component; aqueous component, and optional sun-protecting agent(s) shown in Table 3 is to be viewed as a separate embodiment of the present invention.
Table 3: Exemplary Formulations Ingredient Range of Amounts Tocopherol, Tocotrienol or Mixture 0<% to about 20% Tocopherol, Tocotrienol or Mixture 0<% to about 15% Tocopherol, Tocotrienol or Mixture 0<% to about 10% Tocopherol, Tocotrienol or Mixture 0<% to about 5% Tocopherol, Tocotrienol or Mixture about 1% to about 5% Tocopherol, Tocotrienol or Mixture about 2% to about 5% Tocopherol, Tocotrienol or Mixture about 3% to about 5% Tocopherol, Tocotrienol or Mixture about 4% to about 5% Tocopherol, Tocotrienol or Mixture about 5% to about 9% Tocopherol, Tocotrienol or Mixture about 5% to about 8% Tocopherol, Tocotrienol or Mixture about 5% to about 7% Tocopherol, Tocotrienol or Mixture about 5% to about 6% Tocopherol, Tocotrienol or Mixture about 3% to about 4% Stabilizer/Surfactant Component about 1% to about 20% Stabilizer/Surfactant Component about 5% to about 20% Stabilizer/Surfactant Component about 5% to about 15% Stabilizer/Surfactant Component about 6% to about 14% Stabilizer/Surfactant Component about 7% to about 13% Stabilizer/Surfactant Component about 7% to about 12% Stabilizer/Surfactant Component about 7% to about 11% Stabilizer/Surfactant Component about 7% to about 10% Stabilizer/Surfactant Component about 7% to about 9% Stabilizer/Surfactant Component about 7% to about 8% Stabilizer/Surfactant Component about 10% to about 13% Stabilizer/Surfactant Component about 10% to about 12% Stabilizer/Surfactant Component about 10% to about 11% Stabilizer/Surfactant Component about 9% to about 11% Aqueous Component about 35% to about 99% Aqueous Component about 50% to about 95% Aqueous Component about 55% to about 95% Aqueous Component about 58% to about 95% Aqueous Component about 60% to about 95% Aqueous Component about 65% to about 95% Aqueous Component about 70% to about 95% Aqueous Component about 75% to about 95% Aqueous Component about 80% to about 95% Aqueous Component about 55% to about 60% Aqueous Component about 55% to about 65% Aqueous Component about 55% to about 70% Aqueous Component about 55% to about 75% Aqueous Component about 55% to about 80% Aqueous Component about 55% to about 85% Aqueous Component about 65% to about 90% Cholecalciferol/Ergocalciferol about 0.01% to about 30% Cholecalciferol/Ergocalciferol about 0.01% to about 25% Cholecalciferol/Ergocalciferol about 0.01% to about 20% Cholecalciferol/Ergocalciferol about 0.01% to about 15% Cholecalciferol/Ergocalciferol about 0.01% to about 10% Cholecalciferol/Ergocalciferol about 0.01% to about 5% Cholecalciferol/Ergocalciferol about 0.01% to about 1% Cholecalciferol/Ergocalciferol about 0.01% to about 0.5% Cholecalciferol/Ergocalciferol about 0.01% to about 0.4% Cholecalciferol/Ergocalciferol about 0.01% to about 0.3% Cholecalciferol/Ergocalciferol about 0.01% to about 0.2% Cholecalciferol/Ergocalciferol about 0.2% to about 0.3% Sun-protecting Agent(s) about 0% to about 30% Sun-protecting Agent(s) about 0% to about 25% Sun-protecting Agent(s) about 0% to about 20% Sun-protecting Agent(s) about 0% to about 15% Sun-protecting Agent(s) about 0% to about 10% Sun-protecting Agent(s) about 0% to about 5% Sun-protecting Agent(s) about 5% to about 20% Sun-protecting Agent(s) about 10% to about 20% Sun-protecting Agent(s) about 7% to about 19% - Furthermore, capsule size may be modified by decreasing or increasing the water content; decreasing or increasing the stabilizer/surfactant content; and/or by changing the temperature or the shear in forming lipid microcapsules according to the present disclosure.
- Other embodiments may comprise one or more combinations of the embodiments and/or examples described herein or subsets thereof.
- The discussion herein and the following Examples set forth and illustrate various exemplary embodiments of the present disclosure, which are understood to be illustrative and non-limiting.
- A 5 week study was conducted to demonstrate the effectiveness of the inventive formulations to transdermally deliver vitamin D3 to increase serum vitamin D levels.
- A vitamin D-sunscreen cream formulation of the present invention was prepared within the parameters set forth in Table 4 and as described herein ("test formulation").
Table 4: Test Formulation Vitamin E USP(E) Polyoxyethylene-1-stearyl ether (B72) Sterile USP Water Vitamin D3 USP (30,000IU per gram) in corn oil Zinc Oxide USP micronized powder (8%) - All excipients used in the test formulation were GRAS. The hydrophobic and hydrophilic components were admixed separately before combining. Zinc Oxide was admixed in the last step.
- Three (3) healthy subjects with screening and baseline serum vitamin D3 levels less than 30ng/ml were selected to participate in the study. Informed consent was obtained.
- Subjects agreed as follows: not to apply moisturizers or other topical skin care or prescription skin care products to the test formulation application sites during the study; to use the sunscreen on areas of potential sun exposure not covered by the test formulation; agreed to apply the test formulation once daily after bathing; to maintain their pre-study lifestyle and to not change daily activities that would change their exposure to the sun; and not to ingest vitamins or other supplements that contain any form of vitamin D within 30 days of the first visit.
- Subjects were dosed with the test formulation by once daily application to the neck, shoulders, arms, chest, thighs and/or abdomen following bathing, as follows:
Week 1 = 2.5 gram;Week 2 = 5.0 gram;Weeks - Vitamin D3 levels were measured at Days -7 (Screening), 0 (Baseline), 7, 14, 21, 28 and 35.
- Irritation, desquamation, and subject queried stinging/burning/itching at the application site of the test formulation were graded as follows: 0 = None; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe.
- Weekly vitamin D levels between baseline and end of study were used for safety assessment (vitamin D3 excess, not to exceed 100ng/ml at any time during the study) and local tolerability (skin irritation or other cutaneous side effects) assessments at the test formulation application sites were conducted at Days -14 to -2, 0, 7, 14, 21, 28 and 35.
- A pre-specified endpoint was a numerically significant difference between baseline vitamin D3 and end of study vitamin D3. Vitamin D3 levels were assessed as percent change from baseline. Ordinal investigator tolerability assessments were evaluated with a Mann Whitney two-tailed t-test for nonparametric data.
-
Table 5: Serum vitamin D3 Levels Week -1 to Week 5Vitamin D3 Levels (ng/ml) Subject Day -7 (Screen) Day 0 (Baseline) Day 7 Day 14 Day 21 Day 28 Day 35 1 14.7 16.0 15.2 14.8 14.6 14.9 17.9 2 18.3 18.6 17.4 20.0 18.4 21.8 21.9 3 16.3 17.5 17.0 16.7 17.1 20.7 23.1 -
FIGS.1A-1C ;2A-2C ; and3A-3C show analysis of the data in Table 5, as follows: -
FIGS. 1A-1C show vitamin D3 levels measured from baseline (Week 0) to the end of study (Week 5). Mean increase in vitamin D3 levels was 21% (per protocol analysis). -
FIGS.2A-2C show vitamin D3 levels measured from the lowest D3 level to the end of study (Week 5). Mean increase in vitamin D3 levels was 30% (by intent analysis). -
FIGS.3A-3C show vitamin D3 levels measured fromWeek 3 to the end of study (Week 5). Mean increase in vitamin D3 levels was 26% (per best case analysis). - As shown in Table 5 and as illustrated in each of
FIGS.1-3 discussed above, there was a significant increase in the serum vitamin D levels of each ofSubjects - In certain other embodiments, and as will be understood by those of the skill in the art, topical formulations and lipid microcapsules according to the present invention may further include other ingredients, as necessary to render formulations suitable for specific applications.
- Once given the above disclosure, many other features, modifications, and improvements will become apparent to the skilled artisan. Such features, modifications, and improvements are therefore considered to be part of this invention, without limitation imposed by the example embodiments described herein. Moreover, any word, term, phrase, feature, example, embodiment, or part or combination thereof, as used to describe or exemplify embodiments herein, unless unequivocally set forth as expressly uniquely defined or otherwise unequivocally set forth as limiting, is not intended to impart a narrowing scope to the invention in contravention of the ordinary meaning of the claim terms by which the scope of the patent property rights shall otherwise be determined.
- The citation of references herein shall not be construed as an admission that such is prior art to the present invention.
-
-
U.S. Patent No. 4,182,330 to Michaels . -
U.S. Patent No. 4,235,871 to Papahadjopoulos et al. -
U.S. Patent No. 4,356,167 to Kelly . -
U.S. Patent No. 4,610,868 to Fountain et al. -
U.S. Patent No. 4,725,442 to Haynes . -
U.S. Patent No. 4,744,989 to Payne et al. -
U.S. Patent No. 4,824,675 to Wong et al. -
U.S. Patent No. 4,911,928 to Wallach . -
U.S. Patent No. 5,120,710 to Liedtke . -
U.S. Patent No. 5,152,923 to Weder et al. -
U.S. Patent No. 5,629,021 to Wright . - GB Patent No.
GB2078543 - Rolland, A. et al. (1992) "New Macromolecular Carriers for Drugs. I. Preparation and Characterization of Polyoxyethylene-b-isoprene-b-oxyethylene Block Copolymer Aggregates" Journal of Applied Polymer Science, 44: 1195-1203.
Claims (12)
- A topical formulation, comprising: a lipid microcapsule, said lipid microcapsule comprising: (a) tocopherol, tocotrienol, or mixtures thereof; (b) a stabilizer/surfactant component selected from polyoxyethylene (2) stearyl ether, polyoxyethylene (2) cetyl ether and a mixture thereof; and (c) an aqueous component,wherein said lipid microcapsule is formed by the steps (i) adding said tocopherol, tocotrienol, or mixtures thereof to said stabilizer/surfactant component to produce a mixture; (ii) heating said mixture; and (iii) adding said aqueous component to said heated mixture thereby forming said lipid microcapsule; andwherein said lipid microcapsule is free of a phospholipid charge-producing agent.
- A topical formulation according to claim 1, wherein said tocopherol, tocotrienol, or mixtures thereof is present in said lipid microcapsule in an amount of about 0<% to about 8% based on the total weight of said topical formulation; and said stabilizer/surfactant component is present in said lipid microcapsule in an amount of about 7% to about 13% based on the total weight of said topical formulation.
- A topical formulation according to claim 1 or 2, wherein said tocopherol, tocotrienol, or mixtures thereof; said stabilizer/surfactant component; and said aqueous component form, in combination, a lipophilic phase of said topical formulation.
- A topical formulation according to claim 1 or 2, wherein said aqueous component of said lipid microcapsule is a physiologically compatible solution.
- A topical formulation according to claim 1 or 2, wherein said topical formulation is free of one or more of the following: a skin penetration enhancer; a preservative compound; a steroid; and an oil compound.
- A topical formulation according to claim 1 or 2, further comprising one or more transdermal active agents; said one or more transdermal active agents being dissolved, suspended or encapsulated in said lipid microcapsule.
- A topical formulation according to claim 6, wherein said one or more transdermal active agents is a vitamin D compound.
- A topical formulation according to claim 7, wherein said vitamin D compound is a physiologic biological vitamin D compound selected from the group consisting of cholecalciferol, ergocalciferol, and mixtures thereof, and is present in said topical formulation in an amount of about 0<% to about 30%.
- A topical formulation according to claim 6, further comprising one or more topical active agents present outside said lipid microcapsule such that said lipid microcapsule is free of said one or more topical active agents.
- A topical formulation according to claim 9, wherein said one or more topical active agents is a sun-protecting agent present in said topical formulation in an amount of about 0<% to about 30% based on the total weight of said topical formulation.
- A topical formulation according to claim 1 or 2, wherein said topical formulation is in the form of a cream, gel, liquid, lotion, solution, spray, emulsion, aerosol, or a combination thereof.
- A topical formulation according to any of claims 1 to 11 for use in treating a disorder or disease associated with vitamin D deficiency or vitamin D insufficiency, wherein the formulation also comprises a transdermal active agent wherein said transdermal active agent is a vitamin D compound; said disorder of disease associated with vitamin D deficiency or vitamin D insufficiency being selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502810P | 2011-06-29 | 2011-06-29 | |
PCT/US2012/045095 WO2013003803A1 (en) | 2011-06-29 | 2012-06-29 | Topical formulations including lipid microcapsule delivery vehicles and their uses |
Publications (4)
Publication Number | Publication Date |
---|---|
EP2726071A1 EP2726071A1 (en) | 2014-05-07 |
EP2726071A4 EP2726071A4 (en) | 2015-04-15 |
EP2726071C0 EP2726071C0 (en) | 2023-10-11 |
EP2726071B1 true EP2726071B1 (en) | 2023-10-11 |
Family
ID=47424580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12804394.0A Active EP2726071B1 (en) | 2011-06-29 | 2012-06-29 | Topical formulations including lipid microcapsule delivery vehicles and their uses |
Country Status (8)
Country | Link |
---|---|
US (1) | US11065206B2 (en) |
EP (1) | EP2726071B1 (en) |
JP (1) | JP6322575B2 (en) |
CN (1) | CN104023717B (en) |
AU (1) | AU2012275091B2 (en) |
CA (1) | CA2877102C (en) |
HK (1) | HK1201468A1 (en) |
WO (1) | WO2013003803A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8470304B2 (en) | 2009-08-04 | 2013-06-25 | Avidas Pharmaceuticals Llc | Therapeutic vitamin D sun-protecting formulations and methods for their use |
US20220218723A1 (en) * | 2021-01-13 | 2022-07-14 | The Daily Suncare, LLC | Compositions for facilitating topical administration of vitamin d while protecting against uv light |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0357773A1 (en) * | 1987-02-27 | 1990-03-14 | Terumo Kabushiki Kaisha | Process for preparing liposomes |
WO1997037637A1 (en) * | 1996-04-04 | 1997-10-16 | Ortho Pharmaceutical Corporation | Liposome-based topical vitamin d formulation |
US20050208082A1 (en) * | 2004-03-20 | 2005-09-22 | Papas Andreas M | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4182330A (en) | 1977-07-25 | 1980-01-08 | Alza Corporation | Means for administering amphipathic medicament |
US4356167A (en) | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
DE43327T1 (en) | 1980-07-01 | 1983-01-05 | L'Oreal, 75008 Paris | METHOD FOR PRODUCING STABLE DISPERSIONS IN AN AQUEOUS PHASE OF AT LEAST ONE LIQUID, NOT WATER-MISCIPABLE, AND THE CORRESPONDING DISPERSIONS. |
US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
US4610868A (en) | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4572915A (en) * | 1984-05-01 | 1986-02-25 | Bioglan Laboratories | Clear micellized solutions of fat soluble essential nutrients |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4824675A (en) | 1987-07-13 | 1989-04-25 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
DE3919982A1 (en) | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | ORAL LIPID MEDICINE FORM |
CH677886A5 (en) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
FR2725369B1 (en) * | 1994-10-07 | 1997-01-03 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITION CONSISTING OF AN OIL IN WATER EMULSION BASED ON OIL CELLS PROVIDED WITH A LAMELLAR LIQUID CRYSTAL COATING |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
EP0897300A4 (en) * | 1995-10-10 | 2000-07-05 | Marilyn Strube | Treatment of pruritus with vitamin d and analogs thereof |
US5720948A (en) * | 1995-11-07 | 1998-02-24 | Helene Curtis Inc. | Non-ionic surfactant emulsion vehicles and their use for deposition of drug into and across skin |
HU226610B1 (en) * | 1998-03-04 | 2009-04-28 | Teijin Ltd | Activated vitamin d3 emulsion-type lotions |
PL193824B1 (en) * | 1998-12-23 | 2007-03-30 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
JP4637991B2 (en) * | 1999-07-27 | 2011-02-23 | 株式会社資生堂 | Microcapsule and manufacturing method thereof |
JP2002338458A (en) * | 2001-03-09 | 2002-11-27 | Eau De Faveur:Kk | Skin care preparation |
US20040170582A1 (en) * | 2001-07-31 | 2004-09-02 | Anne-Cecile Harivel | Sunscreen composition |
EP1684724A4 (en) * | 2003-11-19 | 2008-04-02 | Barnes Jewish Hospital | Enhanced drug delivery |
PL1811979T3 (en) * | 2004-09-27 | 2009-04-30 | Sigmoid Pharma Ltd | Microcapsules comprising a methylxanthine and a corticosteroid |
US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
AU2008206087A1 (en) * | 2007-01-18 | 2008-07-24 | Mark A. Pinsky | Materials and methods for delivering antioxidants into the skin |
JP4341983B2 (en) * | 2007-12-07 | 2009-10-14 | 株式会社資生堂 | Topical skin preparation |
KR20110040936A (en) * | 2008-07-18 | 2011-04-20 | 바이오모드 컨셉츠 인코포레이티드 | Articles of manufacture releasing an active ingredient |
US20100080768A1 (en) * | 2008-09-26 | 2010-04-01 | Mcgraw Thomas L | Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin |
US8470304B2 (en) * | 2009-08-04 | 2013-06-25 | Avidas Pharmaceuticals Llc | Therapeutic vitamin D sun-protecting formulations and methods for their use |
US8784787B2 (en) * | 2009-10-23 | 2014-07-22 | Dow Corning Toray Co., Ltd. | Co-modified organopolysiloxane |
-
2012
- 2012-06-29 AU AU2012275091A patent/AU2012275091B2/en active Active
- 2012-06-29 EP EP12804394.0A patent/EP2726071B1/en active Active
- 2012-06-29 WO PCT/US2012/045095 patent/WO2013003803A1/en active Application Filing
- 2012-06-29 CA CA2877102A patent/CA2877102C/en active Active
- 2012-06-29 CN CN201280042074.0A patent/CN104023717B/en active Active
- 2012-06-29 JP JP2014519195A patent/JP6322575B2/en active Active
- 2012-06-29 US US14/129,747 patent/US11065206B2/en active Active
-
2015
- 2015-03-02 HK HK15102075.7A patent/HK1201468A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0357773A1 (en) * | 1987-02-27 | 1990-03-14 | Terumo Kabushiki Kaisha | Process for preparing liposomes |
WO1997037637A1 (en) * | 1996-04-04 | 1997-10-16 | Ortho Pharmaceutical Corporation | Liposome-based topical vitamin d formulation |
US20050208082A1 (en) * | 2004-03-20 | 2005-09-22 | Papas Andreas M | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
Also Published As
Publication number | Publication date |
---|---|
CA2877102C (en) | 2020-06-30 |
EP2726071C0 (en) | 2023-10-11 |
JP6322575B2 (en) | 2018-05-09 |
AU2012275091B2 (en) | 2017-08-03 |
JP2014522848A (en) | 2014-09-08 |
EP2726071A1 (en) | 2014-05-07 |
US20140348910A1 (en) | 2014-11-27 |
US11065206B2 (en) | 2021-07-20 |
CN104023717B (en) | 2017-08-04 |
CA2877102A1 (en) | 2013-01-03 |
HK1201468A1 (en) | 2015-09-04 |
EP2726071A4 (en) | 2015-04-15 |
CN104023717A (en) | 2014-09-03 |
AU2012275091A1 (en) | 2014-02-20 |
WO2013003803A1 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10206876B2 (en) | Depot formulations of a local anesthetic and methods for preparation thereof | |
JP5886273B2 (en) | Low oil content pharmaceutical emulsion composition containing progestogen | |
RU2379039C2 (en) | External compositions containing adenosyl cobalamin for treatment of skin diseases | |
EP1741433B1 (en) | Pharmaceutical composition comprising an androgen | |
EP2726071B1 (en) | Topical formulations including lipid microcapsule delivery vehicles and their uses | |
CN111481559B (en) | High-concentration fulvestrant composition and preparation method thereof | |
Siddiqua et al. | A REVIEW ON NOVEL APPROACH OF DRUG DELIVERY-ETHOSOMES | |
US20130071471A1 (en) | Pharmaceutical composition for treating atopic dermatitis | |
PALLAM et al. | DESIGN, PREPARE AND CHARACTERIZATION OF ECONAZOLE ETHOSOMAL GEL | |
WO2013189477A1 (en) | Emulsion for pharmaceutical use and method for the production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140129 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150316 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/593 20060101ALI20150310BHEP Ipc: A61K 31/592 20060101ALI20150310BHEP Ipc: A61K 45/06 20060101ALI20150310BHEP Ipc: A61K 9/48 20060101ALI20150310BHEP Ipc: A61P 3/02 20060101ALI20150310BHEP Ipc: A61K 31/355 20060101AFI20150310BHEP Ipc: A61K 9/50 20060101ALI20150310BHEP Ipc: A61K 9/127 20060101ALI20150310BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170410 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20230406BHEP Ipc: A61P 37/06 20060101ALI20230406BHEP Ipc: A61P 35/00 20060101ALI20230406BHEP Ipc: A61P 31/06 20060101ALI20230406BHEP Ipc: A61P 25/00 20060101ALI20230406BHEP Ipc: A61P 19/00 20060101ALI20230406BHEP Ipc: A61P 13/12 20060101ALI20230406BHEP Ipc: A61P 9/14 20060101ALI20230406BHEP Ipc: A61P 5/18 20060101ALI20230406BHEP Ipc: A61P 3/10 20060101ALI20230406BHEP Ipc: A61P 1/02 20060101ALI20230406BHEP Ipc: A61K 9/06 20060101ALI20230406BHEP Ipc: A61K 47/14 20060101ALI20230406BHEP Ipc: A61K 9/50 20060101ALI20230406BHEP Ipc: A61P 3/02 20060101ALI20230406BHEP Ipc: A61K 9/127 20060101ALI20230406BHEP Ipc: A61K 9/48 20060101ALI20230406BHEP Ipc: A61K 45/06 20060101ALI20230406BHEP Ipc: A61K 31/592 20060101ALI20230406BHEP Ipc: A61K 31/593 20060101ALI20230406BHEP Ipc: A61K 31/355 20060101AFI20230406BHEP |
|
INTG | Intention to grant announced |
Effective date: 20230508 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012080180 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20231110 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20231212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240211 |